Secreted amyloid β–protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease
The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
To determine whether the presenilin 1 (PS1), presenilin 2 (PS2) and amyloid beta-protein precursor (APP) mutations linked to familial Alzheimer's disease (FAD) increase the extracellular concentration of amyloid beta-protein (A beta) ending at A beta 42(43) in vivo, we performed a blinded comparison of plasma A beta levels in carriers of these mutations and controls. A beta 1-42(43) was elevated in plasma from subjects with FAD-linked PS1 (P < 0.0001), PS2N1411 (P = 0.009), APPK670N,M671L (P < 0.0001), and APPV7171 (one subject) mutations. A beta ending at A beta 42(43) was also significantly elevated in fibroblast media from subjects with PS1 (P < 0.0001) or PS2 (P = 0.03) mutations. These findings indicate that the FAD-linked mutations may all cause Alzhelmer's disease by increasing the extracellular concentration of A beta 42(43), thereby fostering cerebral deposition of this highly amyloidogenic peptide.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Aβ is produced by sequential β- and γ-secretase proteolytic cleavage of the amyloid precursor protein (APP) [11–17].”
From Amyloid-β interrupts canonical Sonic hedgehog signaling by distorting primary cilia structure (2018) · cites this paper as [11]
In the citing paper
“Similar to PSEN1 , PSEN2 mutations may also cause increased production of long A 𝛃 peptide species (481, 523), although this needs more investigation.”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [523]
In the citing paper
“It is well established that this mutation causes concomitant increases in secreted A42 and A40 (Cai et al., 1993;Citron et al., 1994;Scheuner et al., 1996).”
From Age-Dependent Changes in Brain, CSF, and Plasma Amyloid β Protein in the Tg2576 Transgenic Mouse Model of Alzheimer's Disease (2001) · cites this paper as Scheuner et al., 1996
In the citing paper
“In a previous study of human plasma (Scheuner et al., 1996), we showed that the Swedish APP K670N,M671L mutation increases both A42 and A40 and that other FAD-linked APP, PS1, and PS2 mutations selectively increase A42.”
From Age-Dependent Changes in Brain, CSF, and Plasma Amyloid β Protein in the Tg2576 Transgenic Mouse Model of Alzheimer's Disease (2001) · cites this paper as Scheuner et al., 1996
In the citing paper
“In that report, we suggested that cerebral A deposition in FAD occurs because of an increase in CNS A that develops as part of a generalized genetic effect that also increases plasma A.”
From Age-Dependent Changes in Brain, CSF, and Plasma Amyloid β Protein in the Tg2576 Transgenic Mouse Model of Alzheimer's Disease (2001) · cites this paper as Scheuner et al., 1996
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659
Self-citationCloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease
Sherrington, R., Rogaev, E. I., Liang, Y., Rogaeva, E. A., Levesque, G., Ikeda, M., Chi, H., Lin, C., Li, G., Holman, K., et al. (1995) · Nature · doi:10.1038/375754a0 · Cited by 4,051
Self-citationCandidate gene for the chromosome 1 familial Alzheimer’s disease locus
Levy-Lahad, E., Wasco, W., Poorkaj, P., Romano, D. M., Oshima, J., Pettingell, W. H., Yu, C.-E., Jondro, P. D., Schmidt, S. D., Wang, K., et al. (1995) · Science · doi:10.1126/science.7638622 · Cited by 2,577
Self-citationJarrett, J. T., & Lansbury, P. T. (1993) · Cell · doi:10.1016/0092-8674(93)90635-4 · Cited by 2,178
Rogaev, E. I., Sherrington, R., Rogaeva, E. A., Levesque, G., Ikeda, M., Liang, Y., Chi, H., Lin, C., Holman, K., Tsuda, T., et al. (1995) · Nature · doi:10.1038/376775a0 · Cited by 2,052
Self-citationJarrett, J. T., Berger, E. P., & Lansbury, P. T. (1993) · Biochemistry · doi:10.1021/bi00069a001 · Cited by 2,022
Amyloid β-peptide is produced by cultured cells during normal metabolism
Haass, C., Schlossmacher, M. G., Hung, A. Y., Vigo-Pelfrey, C., Mellon, A., Ostaszewski, B. L., Lieberburg, I., Koo, E. H., Schenk, D., Teplow, D. B., et al. (1992) · Nature · doi:10.1038/359322a0 · Cited by 1,921
Self-citationCitron, M., Oltersdorf, T., Haass, C., McConlogue, L., Hung, A. Y., Seubert, P., Vigo-Pelfrey, C., Lieberburg, I., & Selkoe, D. J. (1992) · Nature · doi:10.1038/360672a0 · Cited by 1,757
Self-citationIsolation and quantification of soluble Alzheimer's β-peptide from biological fluids
Seubert, P., Vigo-Pelfrey, C., Esch, F., Lee, M., Dovey, H., Davis, D., Sinha, S., Schiossmacher, M., Whaley, J., Swindlehurst, C., et al. (1992) · Nature · doi:10.1038/359325a0 · Cited by 1,731
Self-citation
Cited by
Items 1,701–1,800 of 2,576
Noonan, C. W., Reif, J. S., Burch, J. B., Ichinose, T. Y., Yost, M. G., & Magnusson, K. R. (2002) · Journal of Occupational and Environmental Medicine · doi:10.1097/00043764-200208000-00012 · Cited by 16
Presenilin-1 deficiency impairs glutamate-evoked intracellular calcium responses in neurons
Yang, Y., & Cook, D. G. (2004) · Neuroscience · doi:10.1016/j.neuroscience.2003.11.029 · Cited by 17
Öztürk, A., DeKosky, S. T., & Kamboh, M. I. (2006) · Neuroscience Letters · doi:10.1016/j.neulet.2006.07.054 · Cited by 16
Secretases as therapeutic targets in Alzheimer’s disease: patents 2000 – 2004
Larner, A. J. (2004) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.14.10.1403 · Cited by 16
“The vast majority of PS mutations increase the production of Aβ42, presumably mediated by γ-secretase cleavage of APP [40,41], but rare cases of frontotemporal dementia associated with PS1 mutations may reflect a dominant-negative effect (loss of γ-secretase activity) [42], a situation unlikely to be helped by γ-secre…”
BackgroundRegulation of Alzheimer ß-Amyloid Precursor Trafficking and Metabolism
Gandy, S., & Petanceska, S. S. (2001) · Advances in experimental medicine and biology · doi:10.1007/978-1-4615-1249-3_7 · Cited by 22
Morelli, L., Giambartolomei, G. H., Prat, M. I., & Castaño, E. M. (1999) · Neuroscience Letters · doi:10.1016/s0304-3940(99)00023-3 · Cited by 18
Translational considerations for CNS gene therapy
Ryan, D. A., & Federoff, H. J. (2007) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.7.3.305 · Cited by 17
Mann, D. M. A., Pickering-Brown, S. M., Bayatti, N., Wright, A. E., Owen, F., Iwatsubo, T., & Saido, T. C. (1997) · Neuroscience Letters · doi:10.1016/s0304-3940(97)13342-0 · Cited by 16
Presenilin-1 Polymorphism in Alzheimer's Disease and Vascular Dementia
Matsushita, S., Arai, H., Muramatsu, T., Makimoto, K., Nakagawa, T., Sasaki, H., & Higuchi, S. (1997) · Experimental Neurology · doi:10.1006/exnr.1997.6558 · Cited by 16
Parsons, J. T., Churn, S. B., & DeLorenzo, R. J. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00576.x · Cited by 16
“Disturbances of ER function and Ca21 homeostasis have been associated with altered processing of b-amyloid precursor protein caused by mutated presenilins in Alzheimer's disease (Mattson et al. 2000; Scheuner et al. 1996; Mattson and Guo 1999).”
BackgroundDistinct Processing of Endogenous and Overexpressed Recombinant Presenilin 1
Baumann, K., Paganetti, P., Sturchler, C., Wong, C. W., Hartmann, H., Cescato, R., Frey, P., Yankner, B. A., Sommer, B., & Staufenbiel, M. (1997) · Neurobiology of Aging · doi:10.1016/s0197-4580(97)00004-3 · Cited by 16
Alzheimer's disease, amyotrophic lateral sclerosis, and transgenic mice
Bajaj, N. P. S., Irving, N. G., Leigh, P. N., & MILLER, C. C. J. (1998) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.64.6.711 · Cited by 17
Wang, B., Zhong, X., Fields, L. G., Lu, H., Zhu, Z., & Li, L. (2023) · Journal of the American Society for Mass Spectrometry · doi:10.1021/jasms.2c00332 · Cited by 17
American Ginseng for the Treatment of Alzheimer’s Disease: A Review
Shan, M., Bai, Y., Fang, X., Lan, X., Zhang, Y., Cao, Y., Zhu, D., & Luo, H. (2023) · Molecules · doi:10.3390/molecules28155716 · Cited by 16
Eckman, E. A., Clausen, D. M., Solé‐Domènech, S., Lee, C. W., Pereira, C. S., Domalewski, R. J., Nichols, M. R., & Pacheco‐Quinto, J. (2023) · Journal of Neuroscience · doi:10.1523/jneurosci.1318-23.2023 · Cited by 16
Deciphering the Role of Selenoprotein M
Nunes, L. G. A., Cain, A., Comyns, C., Hoffmann, P. R., & Krahn, N. (2023) · Antioxidants · doi:10.3390/antiox12111906 · Cited by 16
Comprehensive annotation of microRNA expression profiles
Sun, B., Yang, F., Hu, F., Huang, N., & Xiao, Z. (2013) · BMC Genetics · doi:10.1186/1471-2156-14-120 · Cited by 15
“(NM_000794), which have been reported to be involved in Alzheimer’s disease [40-42].”
BackgroundUeda, N., Tomita, T., Yanagisawa, K., & Kimura, N. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13586 · Cited by 15
“Some FAD mutations in PS1 selectively increase the production of Ab42, which is very neurotoxic and aggregates more readily than Ab40 (Borchelt et al. 1996; Duff et al. 1996; Scheuner et al. 1996).”
BackgroundMiron, J., Picard, C., Labonté, A., Auld, D. S., & Poirier, J. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-215410 · Cited by 16
Ting, S. K. S., Benzinger, T. L. S., Kepe, V., Fagan, A. M., Coppola, G., Porter, V. R., Hecimovic, S. K., Chakraverty, S., Alvarez-Retuerto, A. I., Goate, A., et al. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-131844 · Cited by 15
The Expression of Presenilin 1 mRNA in Skin Fibroblasts and Brains from Sporadic Alzheimer’s Disease
Ikeda, K., Urakami, K., Arai, H., Wada, K., Wakutani, Y., Ji, Y., Adachi, Y., Okada, A., Kowa, H., Sasaki, H., et al. (2000) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000017246 · Cited by 16
Alternative Approaches in Gene Discovery and Characterization in Alzheimer’s Disease
Ertekin‐Taner, N., Jager, P. L. D., Yu, L., & Bennett, D. A. (2013) · Current Genetic Medicine Reports · doi:10.1007/s40142-013-0007-5 · Cited by 16
“The ability to measure Ab levels in the serum and cerebrospinal fluid (CSF) of AD patients and their relatives [13], and the determination that Ab levels are heritable [14] enabled the first studies utilizing Ab levels as endophenotypes in genetic studies that discovered genetic loci and variants influencing AD risk a…”
BackgroundSung, H. Y., Choi, E. N., Lyu, D., Mook‐Jung, I., & Ahn, J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0099047 · Cited by 16
A critical overview of therapeutic strategy and advancement for Alzheimer's disease treatment
Kuo, Y., & Rajesh, R. (2017) · Journal of the Taiwan Institute of Chemical Engineers · doi:10.1016/j.jtice.2017.05.011 · Cited by 18
Zhang, Y., & Wang, P. (2018) · Medical Science Monitor · doi:10.12659/msm.909596 · Cited by 17
Rivera-Marrero, S., Fernández-Maza, L., Chaviano, S. L., Sablón-Carrazana, M., Bencomo-Martínez, A., Perera‐Pintado, A., Capote, A. P., Zoppolo, F., Kreimerman, I., Pardo, T., et al. (2019) · Current Radiopharmaceuticals · doi:10.2174/1874471012666190102165053 · Cited by 15
Structure-activity relationship of presenilin in γ-secretase-mediated intramembrane cleavage
Cai, T., & Tomita, T. (2020) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2020.02.006 · Cited by 16
Differential effects of angiotensin II receptor blockers on Aβ generation
Liu, J., Liu, S., Tanabe, C., Maeda, T., Zou, K., & Komano, H. (2014) · Neuroscience Letters · doi:10.1016/j.neulet.2014.03.030 · Cited by 16
Zamani, M., Mehri, M., Kollaee, A., Yenki, P., Ghaffarpor, M., Harirchian, M. H., & Shahbazi, M. (2011) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000329514 · Cited by 15
Wagner, S. L., & Muñoz, B. (1999) · Journal of Clinical Investigation · doi:10.1172/jci8729 · Cited by 15
“Clusterin (Apo J) protects against in vitro amyloidβ (1-40) neurotoxicity.”
BackgroundKim, S.-S., Choi, Y.-M., & Suh, Y. (1997) · Journal of Molecular Neuroscience · doi:10.1007/bf02789394 · Cited by 15
Detection of actin cleavage in Alzheimer's disease.
LeBlanc, A. C. (1998) · Europe PMC (PubMed Central) · Cited by 16
Genetic testing for Alzheimerʼs disease: how close is reality?
Blennow, K., & Skoog, I. (1999) · Current Opinion in Psychiatry · doi:10.1097/00001504-199907000-00019 · Cited by 15
Gao, Y., Wei, S., Gao, F., Gao, L., Dang, L., Shang, S., Chen, C., Huo, K., Wang, J., Wang, J., et al. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.615838 · Cited by 17
Synthesis of a potent photoreactive acidic γ-secretase modulator for target identification in cells
Rennhack, A., Jumpertz, T., Neß, J., Baches, S., Pietrzik, C. U., Weggen, S., & Bulic, B. (2012) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2012.08.034 · Cited by 16
Tamaoka, A. (2011) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.100.2469 · Cited by 14
Presenilin Regulates Retinotectal Synapse Formation through EphB2 Receptor Processing
Liu, Z., Thakar, A., Santoro, S. W., & Pratt, K. G. (2018) · Developmental Neurobiology · doi:10.1002/dneu.22638 · Cited by 15
Cathepsin D: A Candidate Link between Amyloid ?-protein and Tauopathy in Alzheimer Disease
Suire, C. N., & Leissring, M. A. (2021) · Journal of Experimental Neurology · doi:10.33696/neurol.2.029 · Cited by 34
“For example, in competition experiments using a fluorogenic peptide substrate to monitor CatD activity, the IC50 of Aβ40 was ~3 µM, whereas that for Aβ42 was a phenomenally low 0.00097 µM, meaning that Aβ42 competitively inhibits CatD with subnanomolar potency [20].”
BackgroundInfluentialSticker-and-spacer model for amyloid beta condensation and fibrillation
Connor, J. P., Quinn, S. D., & Schaefer, C. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.962526 · Cited by 17
“Familial AD mutations in APP, PSEN1, and PSEN2, cause increased production of Aβ , with abnormally high levels of Aβ1−42 relative to Aβ1−40 (Scheuner et al., 1996; Hecimovic et al., 2004; Kumar-Singh et al., 2006; ChávezGutiérrez and Szaruga, 2020).”
BackgroundPresenilin-1 Regulates the Expression of p62 to Govern p62-dependent Tau Degradation
Tung, Y.-T., Wang, B.-J., Hsu, W., Hu, M., Her, G. M., Huang, W., & Liao, Y. (2013) · Molecular Neurobiology · doi:10.1007/s12035-013-8482-y · Cited by 14
Aβ42, Presenilins, and Alzheimer’s Disease
Iwatsubo, T. (1998) · Neurobiology of Aging · doi:10.1016/s0197-4580(98)00027-x · Cited by 14
Sudo, S., Shiozawa, M., Cairns, N. J., & Wada, Y. (2005) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2005.03.043 · Cited by 18
“plasma level of the aggregated form of Ah [13], and AD patients with PS-1 mutation had much more severe Ah1–42 deposits and astrocytosis than non-familial AD patients [14].”
BackgroundNew prospects and strategies for drug target discovery in neurodegenerative disorders
Hilbush, B. S., Morrison, J. H., Young, W. G., Sutcliffe, J. G., & Bloom, F. E. (2005) · NeuroRx · doi:10.1602/neurorx.2.4.627 · Cited by 16
Modeling Neurological Disorders by Human Induced Pluripotent Stem Cells
Kunkanjanawan, T., Noisa, P., & Parnpai, R. (2011) · BioMed Research International · doi:10.1155/2011/350131 · Cited by 18
“in autosomal-dominant familial Alzheimer’s disease [86].”
Ghate, P. S., Sidhar, H., Carlson, G. A., & Giri, R. K. (2014) · SpringerPlus · doi:10.1186/2193-1801-3-161 · Cited by 15
“Mutations in these genes are linked to increased A β formation, specifically the more fibrillo-genic A β 42 peptides (Borchelt et al. 1996b; Scheuner et al. 1996; Tomita et al. 1997), which led to the formulation of the amyloid-β cascade hypothesis.”
Plasma β amyloid and impaired CO2-induced cerebral vasomotor reactivity
van Dijk, E. J., Prins, N. D., Albert Hofman, D., van Duijn, C. M., Koudstaal, P. J., & Breteler, M. M. B. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.03.011 · Cited by 14
Kukharsky, M. S., Овчинников, Р. К., & Бачурин, С. О. (2015) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro20151156103-114 · Cited by 18
Rab21, a Novel PS1 Interactor, Regulates γ-Secretase Activity via PS1 Subcellular Distribution
Sun, Z., Xie, Y., Chen, Y., Yang, Q., Quan, Z., Dai, R., & Qing, H. (2017) · Molecular Neurobiology · doi:10.1007/s12035-017-0606-3 · Cited by 17
Fukuchi, K., Li, L., Hart, M., & Lindsey, J. R. (2000) · International Journal of Experimental Pathology · doi:10.1046/j.1365-2613.2000.00156.x · Cited by 14
“Fax: (205) 975± 5519; E-mail: fukuchi@uab.edu increase production of highly amyloidogenic Ab consisting of 42 amino acids (Borchelt et al. 1996; Duff et al. 1996; Scheuner et al. 1996; Citron et al. 1997; Xia et al. 1997).”
BackgroundCosta, D. A., Nilsson, L. N. G., Bales, K. R., Paul, S. M., & Potter, H. (2004) · Journal of Alzheimer's Disease · doi:10.3233/jad-2004-6508 · Cited by 14
“sembling that of end-stage human AD [3,5,9,15].”
M�ller, A. M., Cronen, C., Kupferwasser, L. I., Oelert, H., M�ller, K.-M., & Kirkpatrick, C. J. (2000) · The Journal of Pathology · doi:10.1002/(sici)1096-9896(200005)191:1<54::aid-path568>3.0.co;2-y · Cited by 100
Alzheimer disease: presenilin springs a leak
Gandy, S., Doeven, M. K., & Poolman, B. (2006) · Nature Medicine · doi:10.1038/nm1006-1121 · Cited by 14
Pinnix, I., Ghiso, J. A., Pappolla, M. A., & Sambamurti, K. (2013) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2013.02.009 · Cited by 15
Role of A β Transport and Clearance in the Pathogenesis and Treatment of Alzheimer’s Disease
Holtzman, D. M., & Zloković, B. V. (2007) · Springer eBooks · doi:10.1007/978-0-387-35135-3_11 · Cited by 16
Soluble amyloid β-protein is increased in frontotemporal dementia with tau gene mutations
Vitali, A., Piccini, A., Borghi, R., Fornaro, P., Siedlak, S. L., Smith, M. A., Gambetti, P. L., Ghetti, B. F., & Tabaton, M. (2004) · Journal of Alzheimer s Disease · doi:10.3233/jad-2004-6106 · Cited by 14
“that in the AD associated with Down’s syndrome (DS) and in the early onset, familial AD associated with gene mutations, Aβ overproduction and accumulation precede tau aggregation [1,2,5,6,14,21,28].”
Uchihara, T., Sanjo, N., Nakamura, A., Han, K., Song, S., George‐Hyslop, P. S., & Fraser, P. E. (2005) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2004.12.011 · Cited by 16
Biological Markers for Alzheimer's Disease
Tapiola, T. (2001) · Cited by 28
Serpents on the road to dementia and death
Beyreuther, K. T., & Masters, C. L. (1997) · Nature Medicine · doi:10.1038/nm0797-723 · Cited by 15
Proteolytic processing of Alzheimer’s disease associated proteins
Haass, C., Grünberg, J., Capell, A., Wild‐Bode, C., Leimer, U., Walter, J., Yamazaki, T., Ihara, I., Zweckbronner, I., Jakubek, C., et al. (1998) · Journal of neural transmission. Supplementum · doi:10.1007/978-3-7091-6467-9_14 · Cited by 18
Article Commentary: Alzheimer's Disease, Diagnosis and the Need for Biomarkers
Hooper, C., Lovestone, S., & Sáinz‐Fuertes, R. (2008) · Biomarker Insights · doi:10.4137/bmi.s682 · Cited by 14
“Furthermore, Aβ1–42 is up-regulated in blood plasma in individuals with familial mutations in APP, PS-1 or PS-2 (Scheuner et al. 1996), but Aβ1–42 is not elevated in sporadic cases of AD, therefore this state biomarker is of limited use in the general population.”
Müller, D., Wiegmann, H., Langer, U., Lenz, S. M., & Nitsch, R. M. (1998) · Journal of Neural Transmission · doi:10.1007/s007020050110 · Cited by 16
“The inherited, familial forms of AD appear to be associated with increased formation of a specific APP derivative, the 42 residue variant of the amyloid â-peptide (Aâ1–42) (Suzuki et al., 1994; Lemere et al., 1996; Scheuner et al., 1996).”
BackgroundAß Toxicity in Alzheimer’s Disease
Klein, W. L. (2001) · Humana Press eBooks · doi:10.1007/978-1-59259-006-3_1 · Cited by 15
Mohan, G. S., & Kumar, R. (2025) · Aging and Disease · doi:10.14336/ad.2025.0472 · Cited by 29
Tao, X., He, J., Zhang, Y., Yin, Y., Yang, C. G., Shang, Y., & Wu, S. (2025) · Neuroscience · doi:10.1016/j.neuroscience.2025.06.018 · Cited by 13
Fernández, S. G., Oria, C. G., Petit, D., Annaert, W. G., Ringman, J. M., Fox, N. C., Ryan, N. S., & Chávez‐Gutiérrez, L. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00832-1 · Cited by 18
Diagnostic methods and biomarkers for Alzheimer’s disease
Bagyinszky, E., Youn, Y. C., An, S. S. A., & Kim, S. (2014) · Toxicology and Environmental Health Sciences · doi:10.1007/s13530-014-0198-5 · Cited by 13
Janssen, L., Dubbelaar, M. L., Holtman, I. R., de Boer-Bergsma, J. J., Eggen, B. J. L., Boddeke, H. W. G. M., Deyn, P. P. D., & Dam, D. V. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2016.11.014 · Cited by 14
Guix, F. X., Sartório, C. L., & ILL‐Raga, G. (2019) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-180089 · Cited by 13
Welty, S., Thathiah, A., & Levine, A. S. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220030 · Cited by 16
Chen, S., & Zacharias, M. (2022) · Biophysical Journal · doi:10.1016/j.bpj.2022.05.023 · Cited by 15
Shaking up the silence: consequences of HMGN1 antagonizing PRC2 in the Down syndrome brain
Farley, S. J., Grishok, A., & Zeldich, E. (2022) · Epigenetics & Chromatin · doi:10.1186/s13072-022-00471-6 · Cited by 13
Nakamura, R., Konishi, M., Higashi, Y., Saito, M., & Akizawa, T. (2023) · Alzheimer s Research & Therapy · doi:10.1186/s13195-023-01229-2 · Cited by 16
Plasma amyloid-β, Aβ1-42, load is reduced by haemodialysis
Rubio, I., Caramelo, C. A., Gil, A., López, M. D., & de Yébenes, J. G. (2006) · Journal of Alzheimer s Disease · doi:10.3233/jad-2006-10413 · Cited by 14
“milial AD caused by presenilin 1 or presenilin 2 mutations plasma Aβ levels are higher than in age matched controls [28,38].”
Geriatric Medicine, Japanese Alzheimer's Disease Neuroimaging Initiative and Biomarker Development
Arai, H., Okamura, N., Furukawa, K., & Kudo, Y. (2010) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.221.87 · Cited by 14
“These mutations enhance proteolytic processing of APP to generate amyloidogenic Aβ (Citron et al. 1992).”
BackgroundInfluentialGlial expression of presenilin epitopes in human brain with cerebral infarction and in astrocytoma
Miake, H., Tsuchiya, K., Nakamura, A., Ikeda, K., Lévesque, L., Fraser, P. E., George‐Hyslop, P. S., Mizusawa, H., & Uchihara, T. (1999) · Acta Neuropathologica · doi:10.1007/s004010051090 · Cited by 13
Chatterjee, P., Gupta, V. B., Fagan, A. M., Jasielec, M. S., Xiong, C., Sohrabi, H. R., Dhaliwal, S. S., Taddei, K., Bourgeat, P., Brown, B. M., et al. (2015) · Current Alzheimer Research · doi:10.2174/1567205012666150204125732 · Cited by 13
Liang, E., Garzone, P. D., Cedarbaum, J. M., Koller, M., Tran, T. T., Xu, V., Ross, B. D., Jhee, S. S., Ereshefsky, L., Pastrak, A., et al. (2013) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.14 · Cited by 13
Law, B. M., Guest, A. L., Pullen, M. W. J., Perkinton, M. S., & Williams, R. J. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170393 · Cited by 14
A toolkit for studying cell surface shedding of diverse transmembrane receptors
Hayward, A. N., Aird, E. J., & Gordon, W. R. (2019) · eLife · doi:10.7554/elife.46983 · Cited by 15
Hasselbalch, H. C., Skov, V., Kjær, L., Sørensen, T. L., Ellervik, C., & Wienecke, T. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-01877-3 · Cited by 13
Park, S. E., Kim, H., Kwon, S. J., Kim, M.-J., Choi, S., Oh, S., Ryu, G. H., Jeon, H. B., Na, D. L., & Chang, J. W. (2021) · Stem Cells International · doi:10.1155/2021/6660186 · Cited by 17
“APP Swedish, which is adjacent to the β - secretase site in APP, is one of the well-known genetic mutations in familial Alzheimer ’ s disease, resulting in increased total A β production [47 – 49].”
The road to load late-onset Alzheimer's disease and a possible way to block it
Whitfield, J. F. (2007) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.11.10.1257 · Cited by 16
“The slow accumulation of A β 42 leading to LOAD is not due to hyperproduction of A β 42 as is the case with the mutant secretases that cause causes most of the early onset [12,13] .”
BackgroundHonda, S., Itoh, F., Yoshimoto, M., Ohno, S., Hinoda, Y., & Imai, K. (2000) · The Journals of Gerontology Series A · doi:10.1093/gerona/55.5.m265 · Cited by 13
The role of beta-amyloid in Alzheimer's disease
Sinha, S. (2002) · Medical Clinics of North America · doi:10.1016/s0025-7125(02)00022-6 · Cited by 14
“A twofold increase in total Ab was found in the plasma of individuals carrying the APPNL mutation, confirming the cellular results [21].”
ResultSoluble Oligomers of the Amyloid β-Protein: Impair Synaptic Plasticity and Behavior
Selkoe, D. J. (2008) · Springer eBooks · doi:10.1007/978-3-540-76330-7_8 · Cited by 18
Self-citationThe regulation of presenilin‐1 by nerve growth factor
Counts, S., Lah, J. J., & Levey, A. I. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00014.x · Cited by 13
“In PS1-linked AD cases, conditioned medium from ®broblasts or plasma from affected individuals contains increased levels of highly ®brillogenic Ab42 (Martins et al. 1995; Scheuner et al. 1996).”
BackgroundAMY plaques in familial AD: Comparison with sporadic Alzheimer’s disease
Lippa, C. F., Schmidt, M. L., Nee, L. E., Bird, T. D., Nochlin, D., Hulette, C., Mori, H., Lee, V. M.-Y., & Trojanowski, J. Q. (2000) · Neurology · doi:10.1212/wnl.54.1.100 · Cited by 16
Self-citationSmith, C., Stanyer, L., & Betteridge, D. J. (2004) · Neuroscience Letters · doi:10.1016/j.neulet.2004.05.094 · Cited by 13
The function of presenilin-1 in amyloid β-peptide generation and brain development
Säftig, P., Hartmann, D., & Strooper, B. D. (1999) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s004060050099 · Cited by 17
Arai, T., Akiyama, H., Ikeda, K., Kondo, H., & Mori, H. (1999) · Brain Research · doi:10.1016/s0006-8993(98)01366-3 · Cited by 13
Neuronal apoptosis as a therapeutic target in neurodegenerative disease
Larner, A. J. (2000) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.10.10.1493 · Cited by 13
“Mutations in genes encoding the amyloid precursor protein (APP) and presenilins (PS1 and PS2) have been shown to cause familial AD; both lead to the production of Aβ [44].”
BackgroundInfluentialMolecular biology for the critical care physician Part II
Santis, G., & Evans, T. W. (1999) · Critical Care Medicine · doi:10.1097/00003246-199905000-00043 · Cited by 13
Mattson, M. P., & Guo, Q. (1999) · The Neuroscientist · doi:10.1177/107385849900500215 · Cited by 15
Production of a heterozygous exon skipping model of common marmosets using gene-editing technology
Sato, K., Sasaguri, H., Kumita, W., Sakuma, T., Morioka, T., Nagata, K., Inoue, T., Kurotaki, Y., Mihira, N., Tagami, M., et al. (2024) · Lab Animal · doi:10.1038/s41684-024-01424-0 · Cited by 14
Presenilin-like GxGD Membrane Proteases Have Dual Roles as Proteolytic Enzymes and Ion Channels
Kuo, I. Y., Hu, J. P., Ha, Y., & Ehrlich, B. E. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.629584 · Cited by 14
Glycosylated clusterin species facilitate Aβ toxicity in human neurons
Foster, E. M., Fernandes, M., Dangla-Valls, A., Hublitz, P., Pangalos, M., Lovestone, S., Ribé, E. M., & Buckley, N. J. (2022) · Scientific Reports · doi:10.1038/s41598-022-23167-z · Cited by 14
Kwon, M. J., Song, Y. R., Kim, J., Kim, J. H., Kang, H. S., Lim, H. S., Kim, M.-J., Kim, N. Y., Hong, S., Choi, Y., et al. (2023) · Biomedicines · doi:10.3390/biomedicines11061606 · Cited by 13
“AD is characterized by a combination of protein abnormalities, specifically aberrant deposits of β-amyloid and tau proteins in the brain [8,9].”
BackgroundHuman iPSC-derived retinal organoids develop robust Alzheimer’s disease neuropathology
James, E., Vielle, A., Cusato, K., Li, H., Lee, B., Parween, S., Howell, A., Johnson, N. R., Chial, H. J., Potter, H., et al. (2024) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2024.1340448 · Cited by 13
Threonine 576 residue of amyloid-β precursor protein regulates its trafficking and processing
Chun, Y. S., Kwon, O.-H., Oh, H. G., Kim, T., McIntire, L. B., Park, M. K., & Chung, S. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.10.037 · Cited by 14
Metadata
- Authors
- Scheuner, D., Eckman, C., Jensen, M., Song, X., Citron, M., Suzuki, N., Bird, T. D., Hardy, J., Hutton, M., Kukull, W., Larson, E., Levy-Lahad, L., Viitanen, M., Peskind, E., Poorkaj, P., Schellenberg, G., Tanzi, R., Wasco, W., Lannfelt, L., Selkoe, D., & Younkin, S.
- Affiliations
- Case Western Reserve University (US)
- Mayo Clinic (US)
- Karolinska Institutet (SE)
- Brigham and Women's Hospital (US)
- Takeda (Japan) (JP)
- University of Washington (US)
- University of South Florida (US)
- Harvard University (US)
- ORCID
- Venue
- Nature Medicine
- Published
- 1996-08
- Volume
- 2
- Issue
- 8
- Pages
- 864-870
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W2101077392
- Semantic Scholar
- ce2164647cb7fb8dcec21d95359a92ec9830047a
- Cited by
- 2,599
- References
- 40
- Citations by year
- 2026: 26 · 2025: 34 · 2024: 58 · 2023: 74 · 2022: 45 · 2021: 66 · 2020: 66 · 2019: 58 · 2018: 53 · 2017: 64 · 2016: 76 · 2015: 72 · 2014: 77 · 2013: 91 · 2012: 96
- FWCI
- 102.76
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- amyloid-beta, familial Alzheimer's disease, presenilin 1, presenilin 2, amyloid precursor protein, APP mutations, amyloid plaques
- MeSH terms
- Alzheimer Disease, Cells, Cultured, Female, Fibroblasts, Humans, Male, Membrane Proteins, Mutation, Peptide Fragments, Amyloid beta-Peptides, Amyloid beta-Protein Precursor, Culture Media, Conditioned, Presenilin-1, Presenilin-2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.